Archive
FTSE100 falls as oil hopes rise; Glaxo bid talk swirls
Britain's blue chips closed the afternoon session lower after uninspiring UK economic data and as energy powerhouse Centrica weighed.
Company
Johnson & Johnson
NYSE:JNJ
Johnson & Johnson is a diversified healthcare products company. The company is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through two segments: Pharmaceutical and MedTech.
152 stories · page 8 of 8
Trending: Johnson & Johnson mulling Glaxo bid?
Open Outcrier tweets that there is “vague takeover chatter” concerning a takeover of drugs giant GlaxoSmithKline by healthcare behemoth Johnson & Johnson.
Wall Street rebounds sharply amid oil rally
An oil rally sent both Brent and U.S. crude briefly above $32 a barrel.
US Risers & Fallers: Morgan Stanley, UnitedHealth, J&J, Amarantus, Avant, Payment Data
Below are some of the main news-driven share price changes as at 11:33 a.m. in New York.
Equities take a pause for breath
Molson Coors is a bright spot on bid speculation, but otherwise it has been a dull day for stocks.
Investments and investor services
Stocks tread water despite Chinese trade data disappointment
Shares are holding their ground, helped by a little bit of bid speculation
Archive
Winning run set to come to an end after Chinese imports shocker
After a long winning streak, investors are set to bank profits following some worrying trade data overnight from China.
J&J shares seesaw on mixed results
The healthcare-docused consumer products group could buy back up to 3.8% of its shares in issue.
Wall Street gains for 4th day on oil rebound; JPMorgan rises
Wall Street headed for its first four-day winning run since January, after a landmark nuclear deal between Tehran and six global powers left sanctions on Iran in place for now, while weaker-than-expected retail sales spurred bets on timing
Wall Street poised to open lower as oil prices retreat on Iran nuclear deal
Wall Street is set to open lower today as investor focus shifted from Greece to the U.S. earnings season and after an Iranian nuclear deal stoked fears of oil-market oversupply. Futures for the Dow Jones Industrial Average slipped 0.1 perce